HRS-7172
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 18, 2025
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Solid Tumor
September 02, 2025
Hengrui Medicine…announced that it received notification from the National Medical Products Administration (NMPA) approving a clinical trial of HRS-7172 tablets in patients with advanced solid tumors harboring RAS mutations or amplifications. [Google translation]
(iis.aastocks.com)
Trial status • Oncology • Solid Tumor
August 28, 2025
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
(clinicaltrials.gov)
- P1 | N=120 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Solid Tumor
1 to 3
Of
3
Go to page
1